LifePoint Health® announced preliminary results with respect to the Company’s previously announced tender offer to purchase for cash (the “Tender Offer”) any and all of its outstanding (i) 8.25% Senior Secured Notes due 2023 (the “2023 Senior Notes”) and (ii) 11.5% Senior Notes due 2024 (the “2024 Senior Notes” and, together with the 2023 Senior Notes, the “Notes” and each, a “Series of Notes” or “Series”) and related consent solicitation (the “Consent Solicitation”). As of 5:00 p.m., New York City time, on February 21, 2020, the early tender deadline with respect to the Tender Offer and Consent Solicitation (the “Early Tender Date”), the Company has been advised by D.F. King & Co., Inc., tender agent and information agent for the Tender Offer and Consent Solicitation, that (i) $622,503,000 (representing approximately 77.81%) of the aggregate principal amount of the 2023 Senior Notes have been validly tendered and not withdrawn in the Tender Offer and (ii) $84,120,000 (representing approximately 24.03%) of the aggregate principal amount of the 2024 Senior Notes have been validly tendered and not withdrawn in the Tender Offer, and corresponding consents have been delivered in the related Consent Solicitation. As of the Early Tender Date, the Company has received the requisite consents to the proposed amendments to the indenture governing the 2023 Senior Notes, including the requisite consents to release all of the collateral securing the 2023 Senior Notes. Each holder who validly tendered its Notes and delivered its consents in the Tender Offer and Consent Solicitation prior to the Early Tender Date, and did not validly withdraw such tendered Notes at or prior to 5:00 p.m., New York City time, on February 21, 2020, the withdrawal deadline with respect to the Tender Offer and Consent Solicitation (the “Withdrawal Deadline”), will receive, if such tendered Notes are accepted for purchase pursuant to the Tender Offer and Consent Solicitation, the Total Consideration. Notes tendered and consents delivered whether prior to, on or after the Withdrawal Deadline may no longer be withdrawn at any time, except as required by applicable law. Holders of Notes of a Series will also receive accrued and unpaid interest from the last interest payment date for such Series of Notes up to, but not including, the applicable settlement date for such Series of Notes accepted for purchase in the Tender Offer. The initial settlement date for Notes validly tendered on or prior to the Early Tender Date is expected to be on or promptly after February 24, 2020. The Tender Offer and Consent Solicitation are being made pursuant to an Offer to Purchase and Consent Solicitation Statement dated February 7, 2020 (the “Tender Offer Materials”), which sets forth a more detailed description of the Tender Offer and Consent Solicitation. Holders of the Notes are urged to carefully read the Tender Offer Materials before making any decision with respect to the Tender Offer and Consent Solicitation. All the conditions described in the Tender Offer Materials, including the Requisite Consent Condition and the Financing Condition (each as defined in the Tender Offer Materials), remain unchanged. The Company has the right, in its sole discretion, to extend, withdraw or terminate the Tender Offer and Consent Solicitation at any time and for any reason, subject to applicable law. The Company is making the Tender Offer and Consent Solicitation only by, and pursuant to, the terms of the Tender Offer Materials. None of the Company, the Dealer Managers, the trustees for each Series of Notes, the tender agent and information agent nor any of their respective affiliates makes any recommendation as to whether or not holders of the Notes should tender or refrain from tendering their Notes.